mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. 2016

Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
a Cellular Oncology group , Biodonostia Institute , San Sebastian , Spain.

BACKGROUND SOX2 and SOX9 are commonly overexpressed in glioblastoma, and regulate the activity of glioma stem cells (GSCs). Their specific and overlapping roles in GSCs and glioma treatment remain unclear. METHODS SOX2 and SOX9 levels were examined in human biopsies. Gain and loss of function determined the impact of altering SOX2 and SOX9 on cell proliferation, senescence, stem cell activity, tumorigenesis and chemoresistance. RESULTS SOX2 and SOX9 expression correlates positively in glioma cells and glioblastoma biopsies. High levels of SOX2 bypass cellular senescence and promote resistance to temozolomide. Mechanistic investigations revealed that SOX2 acts upstream of SOX9. mTOR genetic and pharmacologic (rapamycin) inhibition decreased SOX2 and SOX9 expression, and reversed chemoresistance. CONCLUSIONS Our findings reveal SOX2-SOX9 as an oncogenic axis that regulates stem cell properties and chemoresistance. We identify that rapamycin abrogate SOX protein expression and provide evidence that a combination of rapamycin and temozolomide inhibits tumor growth in cells with high SOX2/SOX9.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077204 Temozolomide A dacarbazine derivative that is used as an alkylating antineoplastic agent for the treatment of MALIGNANT GLIOMA and MALIGNANT MELANOMA. 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one,CCRG 81045,CCRG-81045,M&B 39831,M&B-39831,Methazolastone,NSC 362856,NSC-362856,TMZ-Bioshuttle,TMZA-HE,Temodal,Temodar,Temozolomide Hexyl Ester,CCRG81045,M&B39831,NSC362856,TMZ Bioshuttle
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
January 2018, Oncotarget,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
October 2011, Oncology reports,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
October 2022, Neurological research,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
April 2022, International journal of molecular sciences,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
January 2020, Human cell,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
September 2017, Oncotarget,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
November 2020, Oncology reports,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
July 2011, Biochemical and biophysical research communications,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
June 2021, Experimental neurobiology,
Laura Garros-Regulez, and Paula Aldaz, and Olatz Arrizabalaga, and Veronica Moncho-Amor, and Estefania Carrasco-Garcia, and Lorea Manterola, and Leire Moreno-Cugnon, and Cristina Barrena, and Jorge Villanua, and Irune Ruiz, and Steven Pollard, and Robin Lovell-Badge, and Nicolas Sampron, and Idoia Garcia, and Ander Matheu
July 2021, Stem cell research & therapy,
Copied contents to your clipboard!